TARMAC trial: Time-limited ibrutinib plus CAR T-cell therapy for the treatment of R/R MCL
Here, we summarize the results of the phase II TARMAC trial, published by Minson et al.1 in Blood, of the combination of time-limited ibrutinib and CTL019 CAR T-cells in patients with R/R MCL.